Emyria Ltd. is a healthcare technology and services company. The company is headquartered in Leederville, Western Australia. The company went IPO on 2020-02-12. The firm is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.
Follow-Up Questions
Hiệu suất giá của cổ phiếu EMYRF như thế nào?
Giá hiện tại của EMYRF là $0, đã decreased 0% trong ngày giao dịch cuối cùng.
Chủ đề kinh doanh chính hoặc ngành của Emyria Ltd là gì?
Emyria Ltd thuộc ngành Pharmaceuticals và lĩnh vực là Health Care
Vốn hóa thị trường của Emyria Ltd là bao nhiêu?
Vốn hóa thị trường hiện tại của Emyria Ltd là $NaN
